Vitamin D Status and Vitamin D Receptor Gene Polymorphisms Are Associated with Pelvic Floor Disorders in Women

Jae Hyung Ahn1, Yoo Hun Noh2, Kyung Joo Um1, Hyo Sun Kim1, Sook Cho1

1Department of Obstetrics and Gynecology, Seoul Medical Center, Seoul, Korea, 2Department of Anatomy and Cell Biology, College of Medicine, Chung-Ang University, Seoul, Korea

Objectives: To investigate if vitamin D receptor (VDR) gene polymorphisms and circulating vitamin D levels are associated with pelvic floor disorders (PFDs).

Methods: In this case-control study, 25-hydroxy-vitamin D (25(OH)D) serum levels were analyzed in 47 females with PFDs and 87 healthy females (controls), respectively. The VDR gene polymorphisms were determined by using polymerase chain reaction and performing digestions with 4 restriction enzymes i.e., ApaI, TaqI, FokI, and BsmI. Vitamin D levels of patients were divided into <20 ng/mL, 20 to 30 ng/mL, and ≥30 ng/mL categories.

Results: Our correlative analysis of VDR polymorphisms as a function of the presence of PFD showed that ApaI and BsmI polymorphisms were significantly associated with PFD in vitamin-D-deficiency and insufficiency groups (P < 0.05). Mean vitamin D levels did not differ between the PFD case (13.01 ± 0.84 ng/mL) and control (15.11 ± 1.04 ng/mL) groups (P > 0.05). However, there was a significant difference in the distribution of vitamin D levels between study group and controls using Pearson’s χ² test (<20 ng/mL, 20-30 ng/mL, and >30 ng/mL: 87.2%, 12.8%, and 0% in the study group and 75.9%, 16.1%, and 8.0% in controls, respectively, P < 0.05). Taken together, our observations suggest that vitamin D levels could be associated with PFDs and that 2 polymorphisms (i.e., ApaI and BsmI) in the VDR gene may contribute to an increased prevalence of PFDs in women with insufficient levels of vitamin D.

Conclusions: Examining vitamin D levels and performing a VDR genotype analysis may be helpful for assessing PFD risk. (J Menopausal Med 2018;24:119-126)

Key Words: Genotype · Pelvic floor disorders · Vitamin D · Vitamin D deficiency

Introduction

Pelvic floor disorders (PFDs) are major health problems that can significantly compromise quality of life for affected women. In especially postmenopausal women, PFDs are important issues with heart disease, osteoporosis, and Alzheimer’s disease.1,2 Almost 24% of women are reported to be living with at least one PFD such as urinary incontinence (UI), fecal incontinence (FI) and pelvic organ prolapse (POP).3-5 The female pelvic floor is composed of the levator ani and coccygeus skeletal muscles. These muscles function together to support the visceral contents of the abdominal cavity through sophisticated relationships between ligamentous connective tissue and skeletal muscles. Skeletal and smooth muscles are involved in the function and support of all pelvic viscera.6 Pelvic floor muscle weakness is clinically
observed in women that display PFD symptoms through vaginal bulge or protrusion, involuntary leakage of urine, flatus or feces. Causes of PFD are most likely multifactorial. PFD has previously been associated with age, pregnancy, childbirth, hysterectomy, obesity, race, functional impairment, and cognitive impairment.

Vitamin D is a fat-soluble micronutrient that plays a vital role in calcium and phosphate homeostasis in smooth and skeletal muscle. Vitamin D levels are determined by many factors, such as skin pigmentation, geographic location, and body mass index (BMI). Several studies suggest that serum vitamin D levels may impact functional efficiency of skeletal muscle by regulating calcium homeostasis that in turn affects muscle contractility and by protecting the muscle cellular environment against insulin resistance and inflammation. Vitamin D deficiency (described as exhibiting a serum level <20 ng/mL) has long been clinically associated with impaired muscle strength and loss of muscle mass. Vitamin D insufficiency (25-hydroxy-vitamin D (25(OH)D) serum level 20–30 ng/mL) is a milder form of vitamin D deficiency, affecting 38% to 73% of different populations, and has been related with muscle strength and mobility.

Vitamin D can mediate its effects on muscle through the formation of a complex with a vitamin D receptor (VDR). The VDR gene contains 4 polymorphic regions, each named after the restriction enzymes used to detect them: ApaI (rs7975232), TaqI (rs731236), FokI (rs2228570) and BsmI (rs1544410). Although many studies have demonstrated that VDR gene polymorphisms are associated with muscle strength and bone mineral density (BMD), little research has examined the association of PFD with vitamin D status in Korean women. We conducted a case–control study to evaluate the impact of vitamin D status on PFD symptoms in Korean women, and performed an association analysis between the ApaI, TaqI, FokI, and BsmI VDR polymorphisms and PFD in the same population.

Materials and Methods

1. Study population
The data set comprised 180 women who utilized health examination center and the Obstetrics and Gynecology Clinic at Seoul Medical Center between June and November 2014. All participants provided written informed consent prior to study commencement. This study was approved by the Institutional Review Board of Seoul Medical Center (approval no. 2014–017). Women were excluded if they had any medical conditions that impair vitamin D absorption or metabolism or are known to be a major cause of PFD, including: stage ≥3 chronic kidney disease, chronic liver disease, neurologic disease (cerebral vascular accident, or spinal cord injury), complications of diabetes mellitus with end stage disease (retinopathy, neuropathy, ophthalmic complications, or amputations), gastric bypass, rectovaginal fistula, pelvic floor surgery or pelvic irradiation. Pregnant women were excluded. Patients known to be on vitamin D supplementation were excluded in order to ensure a more homogeneous cohort. Ultimately, 134 women were included in this study (Fig. 1). All eligible participants had a blood sample taken and had sufficient serum available for vitamin D assays. Serum vitamin D panels were processed using liquid chromatography. The 25(OH)D panel included both total 25(OH)D as well as 25(OH)D$_2$ and D$_3$ fractions.

2. Variable definitions
First, a number of standard characteristics were collected for all 134 patients. Using a standard data form, the Electronic Medical Record was abstracted to obtain demographic, medical, and laboratory data. Demographic (i.e., age, height, weight, parity, and status of menopause) and medical characteristics were obtained from the initial history and physical examination documentation. BMI was calculated and reported as kilograms/square meter. Parity (total number of vaginal and cesarean deliveries) was used as a continuous variable in some analyses and categorized as none, 1, 2, 3, or 4 or more births in others.

To identify women with PFD symptoms and divide the data set into cases and controls, all participants filled in standardized questionnaires including a Urinary Distress Inventory (UDI–6), Colorectal Anal Distress Inventory (CRADI–8), POP Distress Inventory (POPDi–6), and Incontinence Impact Questionnaire (IIQ–7). Definitions for UI, FI, and POP were identical to those used by the PFDs Network in their article describing the prevalence of these disorders.
in women surveyed in the 2005 to 2006 the National Health and Nutrition Examination Survey (NHANES),\textsuperscript{23} Specifically, classification of UI was based on the responses to frequency and the amount of leakage (2 NHANES questions) summarized as the “incontinence severity index”. Women with a score of 3 or higher were considered to be incontinent.\textsuperscript{3} FI was defined as at least monthly leakage of solid, liquid, or mucous stool, also based on responses to a combination of type and frequency of symptom question.\textsuperscript{3} POP was considered positive if individuals answered yes to the question, “Do you experience bulging or something falling out you can see or feel in the vaginal area?”, which was derived from the Pelvic Floor Distress Inventory.\textsuperscript{3} Based on these questionnaires, the 134 women in the data set were divided into a case group that had PFD (n = 47) and a control group (n = 87) that did not have PFD. The case and control group were further trichotomized based on vitamin D status as deficient, insufficient and sufficient. For the purposes of this evaluation, vitamin D deficiency was defined as a total serum vitamin D level < 20 ng/mL.\textsuperscript{15} Women with total serum vitamin D levels ≥ 30 ng/mL were classified as being vitamin D sufficient; women with serum levels 20 to 30 ng/mL were grouped as vitamin D insufficient.

3. Genotyping
Genomic DNA was extracted from ethylenediamine–tetraacetic acid (EDTA) whole blood using a salting–out procedure. Genotyping of the following VDR gene polymorphisms was performed using a QIAamp DNA Blood Mini Kit (Qiagen, Inc., Valencia, CA, USA): ApaI (rs7975232), TaqI (rs731236), FokI (rs2228570) and BsmI (rs1544410). These polymorphisms were named after the restriction enzyme that have traditionally been used for their detection.\textsuperscript{24} The VDR gene polymorphisms were analyzed using polymerase chain reaction–restriction fragment length polymorphism analysis.

4. Statistical analysis
Data were analyzed with significance determined at $P < 0.05$ using SPSS version 24.0 (SPSS Inc., Chicago, IL, USA) and values in the text are expressed as means ± standard error of mean. Student’s $t$-tests or one-way analysis of variance (ANOVA) were used for comparisons between PFD and non–PFD group (age, BMI, parity, menopause status and serum total vitamin D levels). Pearson’s $x^2$ test was also used for VDR genotype distribution analysis in PFD.

Results
One hundred and eighty women who had a serum vitamin D level drawn between June and November, 2014, attended health examination center and the Obstetrics and

---

Fig. 1. Flow diagram of the literature search. PFD: pelvic floor disorder.
Gynecology Clinic at Seoul Medical Center were considered in this analysis. Forty-six women were excluded due to the presence of stage III chronic kidney disease, chronic liver disease, neurologic disease, diabetes mellitus with end stage disease, pelvic floor surgery, pelvic irradiation or vitamin D therapy (Fig. 1). Of the remaining 134 women, 47 cases had PFD symptoms, and 87 controls had no PFD symptoms. Each group was further sub-categorized according to vitamin D levels (deficient <20 ng/mL, insufficient 20–30 ng/mL, and sufficient ≥30 ng/mL: Fig. 1).

1. Demographic characteristics

Table 1 documents the demographic characteristics comparing the cases and controls. There were no significant differences in age, BMI, parity, menopause status and mean serum total vitamin D levels between these 2 groups (Table 1).

2. Vitamin D status and PFD symptoms

Our study aimed to identify whether vitamin D status was associated with PFD symptoms. The mean serum vitamin D level in the cases (13.01 ± 0.84) was not significantly different to that of the control group (15.11 ± 1.04) (Table 1). However, there were significant differences between the case and control groups within vitamin D insufficient/deficient women (P < 0.05; Table 2). In the case group, 87.2% (41/47) of the women were vitamin D deficient, 12.8% (6/47) were vitamin D insufficient, and 0.0% (0/47) were vitamin D sufficient. In the control group, 75.9% (66/87) were vitamin D deficient, 16.1% (14/87) were vitamin D insufficient, and 8.0% (7/87) were vitamin D sufficient (Table 2).

3. VDR genotypes and PFD symptoms

In the x² analysis between VDR polymorphisms and PFD, there were no significant differences in PFD diagnosis proportions between the cases and controls for the TaqI and FokI polymorphisms. However, the Apal and BsmI polymorphisms were significantly associated with PFD in the vitamin D deficient and insufficient groups (Table 3). The cases showed an increased frequency of Aa genotype in the Apal polymorphism compared to the frequency of the Aa genotype in this polymorphism in the controls (P < 0.05).

### Table 1. Demographic characteristics of the subjects

| Variable          | Controls (n = 87) | Case (n = 47) | P value |
|-------------------|-------------------|---------------|---------|
| Mean age (years)  | 61.00 ± 1.12      | 60.93 ± 1.42  | 0.890   |
| Mean BMI (kg/m²)  | 23.44 ± 0.41      | 2.24 ± 0.14   | 0.439   |
| Parity            | 2.29 ± 0.10       | 23.96 ± 0.49  | 0.755   |
| Menopause         | 74/87 (85.1)      | 33/47 (70.2)  | 0.069   |
| Serum total 25(OH)D (ng/mL) | 15.11 ± 1.04 | 13.01 ± 0.84 | 0.180   |

The data is presented as mean ± standard deviation or n (%). BMI: body mass index, 25(OH)D: 25-hydroxyvitamin D

### Table 2. Distribution of vitamin D levels in women with/without pelvic floor disorder symptoms

| Serum total 25(OH)D level (ng/mL) | P value |
|-----------------------------------|---------|
| >30                               |         |
| 20-30                             |         |
| <20                               |         |
| Controls                          |         |
| 7 (8.0)                           |         |
| 14 (16.1)                         |         |
| 66 (75.9)                         | 0.048   |
| Cases                             |         |
| 0 (0.0)                           |         |
| 6 (12.8)                          |         |
| 41 (87.2)                         |         |

The data is presented as n (%). 25(OH)D: 25-hydroxy-vitamin D

### Table 3. Vitamin D receptor genotype frequencies in women with/without pelvic floor disorder symptoms within vitamin D insufficient/deficient group

| VDR polymorphism | Controls | Case | P value |
|------------------|----------|------|---------|
| Apal             |          |      |         |
| AA               | 9 (11.3) | 1 (2.1) | 0.038  |
| Aa               | 24 (30.0)| 23 (48.9)| 0.365  |
| aa               | 47 (58.8)| 23 (48.9)| 0.520  |
| TaqI             |          |      |         |
| TT               | 71 (88.8)| 44 (93.6)| 0.031  |
| Tt               | 9 (11.3) | 3 (6.4) |         |
| tt               | 0 (0.0)  | 0 (0.0) |         |
| FokI             |          |      |         |
| FF               | 25 (31.3)| 18 (38.3)|         |
| Ff               | 37 (46.3)| 22 (46.8)|         |
| ff               | 18 (22.5)| 7 (14.9)|         |
| BsmI             |          |      |         |
| BB               | 0 (0.0)  | 0 (0.0) | 0.031   |
| Bb               | 11 (13.8)| 1 (2.1) |         |
| bb               | 69 (86.3)| 46 (97.9)|         |
The frequencies of AA and aa genotypes in ApaI were not increased in the cases compared to the controls in the vitamin D deficient and insufficient groups ($P > 0.05$). In addition, the frequency of bb genotype in BsmI was significantly higher in the cases, while the frequency of Bb genotype in BsmI was significantly higher in the controls ($P < 0.05$). Using $x^2$, ApaI and BsmI VDR polymorphisms are linked, as significant differences in the genotypic frequencies between the cases and controls were observed for Aa × bb genotype (22.5% vs. 46.8%, respectively, $P < 0.05$; Table 4).

### Discussion

This study demonstrated that serum vitamin D status correlates inversely with the prevalence of PFD in women. All women with PFD symptoms in this study were vitamin D insufficient or deficient, defined as exhibiting a 25(OH)D serum level <30 ng/mL or <20 ng/mL. The vitamin D deficient group had a higher PFD incidence rate than the insufficient group. Furthermore, we demonstrated that there was a significant difference in the distribution of VDR genotypes between the cases and controls in vitamin D sufficient/deficient women. To analyze the association between the VDR genotypes and prevalence of PFD, we used the restriction enzymes ApaI, TaqI, FokI and BsmI to genotype 4 polymorphisms in the individuals, each polymorphism named after the restriction enzyme used to genotype it: ApaI (rs7975232), TaqI (rs731236), FokI (rs2228570), and BsmI (rs1544410). The Aa (ApaI) and bb (BsmI) genotype frequencies were higher in the cases than in the controls. To our knowledge, this is the first study to demonstrate an association between VDR gene polymorphisms and PFD.

Our findings are supported by previous clinical studies suggesting that vitamin D deficiency is more prevalent in women with PFD than in the general population, Parker-Autry and colleagues performed a retrospective study (n = 394) and found that women with PFD had significantly lower levels of vitamin D ($29.3 ± 11.5$ ng/mL) compared to women without PFD ($35.0 ± 14.1$ ng/mL) ($P < 0.001$). In addition, this study demonstrated that higher CRADI-8 scores and IIQ-7 scores were associated with vitamin D insufficiency. Badalian and Rosenbaum performed a cross-sectional analysis using 2005 to 2006 the NHNES data (n = 1,881) and observed that mean vitamin D levels were significantly lower for women with PFD. In addition, they showed significantly decreased risks of PFD with increasing vitamin D levels in all women aged 20 or older (odds ratio [OR] = 0.94; 95% confidence interval [CI], 0.88–0.99) and in subset of women 50 years and older (OR = 0.92; 95% CI, 0.85–0.99).

Vitamin D increases skeletal muscle cell proliferation and muscle fiber size in vitro. Vitamin D may be instrumental for skeletal muscle functional efficiency by regulating calcium homeostasis to affect muscle contractility and by protecting the muscle cellular environment against inflammation. Thus, insufficient vitamin D levels may affect various pathophysiologic pathways and contribute to PFDs by disrupting VDR expression and calcium homeostasis in pelvic floor skeletal and visceral musculature. These mechanisms may explain our observation of increased vitamin D deficiency in women with PFD symptoms compared to controls.

Previous studies show that VDR gene polymorphisms are associated with muscle strength, BMD, and various diseases. As far as we know, no previous studies have investigated the effect of the VDR gene polymorphisms on PFD. In this study, we demonstrated that VDR gene polymorphisms were not associated with serum 25(OH)D levels. Although no overall association was found between TaqI or FokI and the prevalence of PFD, we observed a significant association between ApaI or BsmI genotypes and PFD in vitamin D insufficient/deficient women. Regarding the ApaI polymorphism, the frequency of heterozygotes (Aa) was significantly higher in the cases than in the controls, and the frequency of homozygotes (AA and aa) was lower in cases than in controls in vitamin D insufficient/deficient women. Although ApaI–composition of common population are more heterozygotes than homozygotes, we showed that

### Table 4. Linked vitamin D receptor genotype frequencies in women with/without pelvic floor disorder symptoms within vitamin D insufficient/deficient group

|          | AA × Bb | Aa × Bb | aa × Bb | AA × bb | Aa × bb | aa × bb |
|----------|---------|---------|---------|---------|---------|---------|
| Controls | 3 (3.8) | 6 (7.5) | 2 (2.5) | 6 (7.5) | 18 (22.5) | 45 (56.3) |
| Cases    | 0 (0.0) | 1 (2.1) | 0 (0.0) | 1 (2.1) | 22 (46.8) | 23 (48.9) |
| $P$ value|         |         |         |         | 0.032    |         |
frequency of aa genotype in non-PFD group was highest. Therefore, it is plausible that the prevalence of PFD in heterozygote women may be higher than in homozygote women.

BsmI is also associated with skeletal muscle function. The b (rather than B) allele is associated with lower fat-free mass and hamstring strength in healthy women aged 20 to 39 years, whereas, in non-obese elderly women, both handgrip and quadriceps strength are higher in those with the bb genotype.27,28 Barr et al.36 reported that the bb homozygote of BsmI is associated with higher serum 25(OH)D, lower parathyroid hormone and stronger measures of muscle force. Our report showed that the frequency of bb homozygotes in the cases was significantly higher than in the controls, and the heterozygote frequency was lower in cases than in the controls in vitamin D insufficient/deficient women. Furthermore, the frequency of a combination of ApaI and BsmI genotypes (Aa/bb) was significantly higher in the PFD group in vitamin D insufficient/deficient women and was double the number of individuals with the same genotype in the non-PFD group. Both the ApaI and BsmI polymorphisms are located at the 3' end of the VDR gene.24 It is reported that the ApaI, BsmI, and TaqI polymorphisms are in strong linkage disequilibrium. Morrison et al.37 reported that the BsmI and ApaI restriction sites are in close proximity in Caucasian populations. In young Chinese women research, Wang et al.33 showed that VDR gene ApaI and BsmI polymorphisms rather than TaqI were associated with muscular strength. Therefore, we suggest that vitamin D insufficient/deficient women with an Aa/bb genotype may have a higher risk of developing PFD.

Several limitations of this study should be addressed. First, sample sizes are limited; thus only large genotype effects could be detected and there was not enough statistical power to detect genotype interaction effects. The size of the vitamin D sufficient group was too small to compare with vitamin D insufficient/deficient women. Second, the race of the subjects was limited to Koreans. VDR genotypes vary among racial groups; therefore, a variety of studies in different races will be needed to obtain a fuller understanding.

Conclusion

In conclusion, vitamin D insufficiency may influence the prevalence of PFD in ways that are as yet unclear, possibly involving pelvic floor skeletal muscle weakness. Furthermore, the prevalence of PFD may be affected by variations in the VDR genotype. Our study provides meaningful results to understand the relationship between VDR gene polymorphisms and PFD. Particularly, the ApaI and BsmI genotypes of the VDR gene may be related to an increased prevalence of PFD in women. As vitamin D insufficiency of women is very common among Koreans (>90%),38,39 we suggest that vitamin D status and VDR genotype analysis would be helpful for assessing the risk of PFDs in these women.

Acknowledgement

This study was supported by the research fund from Research Institute of Seoul Medical Center, Republic of Korea (grant#14–c06).

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

References

1. Yi SS, Hwang E, Baek HK, Kim TH, Lee HH, Jun HS, et al, Application of bioactive natural materials–based products on five women’s diseases, J Menopausal Med 2015; 21: 121–5.
2. Song HJ, Kim TH, Lee HH, Kim JM, Park YJ, Lee A, et al, Cell therapy products in Alzheimer disease, J Menopausal Med 2017; 23: 1–4.
3. Nygaard I, Barber MD, Burgio KL, Kenton K, Meikle S, Schaffer J, et al, Prevalence of symptomatic pelvic floor disorders in US women, JAMA 2008; 300: 1311–6.
4. Greer WJ, Richter HE, Bartolucci AA, Burgio KL, Obesity and pelvic floor disorders: a systematic review, Obstet Gynecol 2008; 112: 341–9.

https://doi.org/10.6118/jmm.2018.24.2.119
5. Chen GD. Pelvic floor dysfunction in aging women. Taiwan J Obstet Gynecol 2007; 46: 374–8.
6. Parker–Autry CY, Burgio KL, Richter HE. Vitamin D status: a review with implications for the pelvic floor. Int Urogynecol J 2012; 23: 1517–26.
7. Parker–Autry CY, Markland AD, Ballard AC, Downas–Gunn D, Richter HE. Vitamin D status in women with pelvic floor disorder symptoms, Int Urogynecol J 2012; 23: 1699–705.
8. Roobzeh N, Darvish L, Acacia nilotica: new plant for help in pelvic organ prolapse. J Menopausal Med 2016; 22: 129–30.
9. Kepenekci I, Keskinkilic B, Akinsu F, Cakir P, Elhan AH, Erkek AB, et al. Prevalence of pelvic floor disorders in the female population and the impact of age, mode of delivery, and parity, Dis Colon Rectum 2011; 54: 85–94.
10. Hunskaar S, Arnold EP, Burgio K, Diokno AC, Herzog AR, Moalli PA, Jones Ivy S, Meyn LA, Zyczynski HM. Risk factors associated with pelvic floor disorders in women under going surgical repair. Obstet Gynecol 2003; 101: 869–74.
11. Hendrix SL, Clark A, Nygaard I, Aragaki A, Barnabei V, McTernan A. Pelvic organ prolapse in the Women’s Health Initiative: gravity and gravidity. Am J Obstet Gynecol 2002; 186: 1160–6.
12. Gürel H, Gürel SA. Pelvic relaxation and associated risk factors: the results of logistic regression analysis, Acta Obstet Gynecol Scand 1999; 78: 290–3.
13. Uustal Fornell E, Wingren G, Kjølhede P. Factors associated with pelvic floor dysfunction with emphasis on urinary and fecal incontinence and genital prolapse: an epidemiological study, Acta Obstet Gynecol Scand 2004; 83: 383–9.
14. Moalli PA, Jones Ivy S, Meyn LA, Zyczynski HM, Risk factors associated with pelvic floor disorders in women undergoing surgical repair, Obstet Gynecol 2003; 101: 869–74.
15. Parker–Autry CY, Gleason JL, Griffin RL, Markland AD, Richter HE. Vitamin D deficiency is associated with increased fecal incontinence symptoms, Int Urogynecol J 2014; 25: 1483–9.
16. Kim TH, Lee HH, Kim JM, Choi SD, Lee A, Hwang SY, et al. Expression of vitamin D receptor in seminal vesicles of cholesterol formula mice, J Menopausal Med 2015; 21: 89–92.
17. Lips P, Binkley N, Pfeifer M, Recker R, Samanta S, Cohn DA, et al. Once–weekly dose of 8400 IU vitamin D(3) compared with placebo: effects on neuromuscular function and tolerability in older adults with vitamin D insufficiency, Am J Clin Nutr 2010; 91: 985–91.
18. Holick MF, Chen TC, Lu Z, Sauter E. Vitamin D and skin physiology: a D–lightful story, J Bone Miner Res 2007; 22 Suppl 2: V28–33.
19. Ward KA, Das G, Roberts SA, Berry JL, Adams JE, Rawer R, et al. A randomized, controlled trial of vitamin D supplementation upon musculoskeletal health in postmenarchal females, J Clin Endocrinol Metab 2010: 95: 4643–51.
20. Zhu K, Austin N, Devine A, Bruce D, Prince RL, A randomized controlled trial of the effects of vitamin D on muscle strength and mobility in older women with vitamin D insufficiency, J Am Geriatr Soc 2010: 58: 2063–8.
21. Bischoff HA, Stühelin HB, Dick W, Akos R, Knecht M, Salis C, et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial, J Bone Miner Res 2003; 18: 343–51.
22. Dhesi JK, Jackson SH, Bearne LM, Moniz C, Hurley MV, Swift CG, et al. Vitamin D supplementation improves neuromuscular function in older people who fall, Age Ageing 2004: 33: 589–95.
23. Badaliski SS, Rosenbaum PF. Vitamin D and pelvic floor dysfunction in women: results from the National Health and Nutrition Examination Survey, Obstet Gynecol 2010; 115: 795–803.
24. Windelincx A, De Mars G, Beunen G, Aerssens J, Delecuse C, Lefevere J, et al. Polymorphisms in the vitamin D receptor gene are associated with muscle strength in men and women, Osteoporos Int 2007: 18: 1235–42.
25. Ranganathun P. Genetics of bone loss in rheumatoid arthritis—role of vitamin D receptor polymorphisms, Rheumatology (Oxford) 2009: 48: 342–6.
26. Arai H, Miyamoto K, Taketani Y, Yamamoto H, Iemori Y, Morita K, et al. A vitamin D receptor gene polymorphism in the translation initiation codon: effect on protein activity and relation to bone mineral density in Japanese women, J Bone Miner Res 1997: 12: 915–21.
27. Geusens P, Vandervyver C, Vanhoof J, Cassiman JJ, Boonen S, Raus J. Quadriceps and grip strength are related to vitamin D receptor genotype in elderly nonobese women. J Bone Miner Res 2004; 19: 265–9.
31. Bischoff HA, Borchers M, Gudat F, Duermueller U, Theiler R, Stähelin HB, et al. In situ detection of 1,25-dihydroxyvitamin D3 receptor in human skeletal muscle tissue. Histochem J 2001; 33: 19–24.
32. Vandevyver C, Vanhoof J, Declerck K, Stinissen P, Vanvervost C, Michiels L, et al. Lack of association between estrogen receptor genotypes and bone mineral density, fracture history, or muscle strength in elderly women. J Bone Miner Res 1999; 14: 1576–82.
33. Wang P, Ma LH, Wang HY, Zhang W, Tian Q, Cao DN, et al. Association between polymorphisms of vitamin D receptor gene ApaI, BsmI and TaqI and muscular strength in young Chinese women. Int J Sports Med 2006; 27: 182–6.
34. Curran JE, Vaughan T, Lea RA, Weinstein SR, Morrison NA, Griffiths LR. Association of A vitamin D receptor polymorphism with sporadic breast cancer development. Int J Cancer 1999; 83: 723–6.
35. Balsa JA, Iglesias B, Peromingo R, Conde S, Vazquez C, San-Millan JL, et al. Vitamin D receptor polymorphisms in secondary hyperparathyroidism after Scopinaro’s biliopancreatic diversion. Obes Surg 2010; 20: 1415–21.
36. Barr R, Macdonald H, Stewart A, McGuigan F, Rogers A, Eastell R, et al. Association between vitamin D receptor gene polymorphisms, falls, balance and muscle power: results from two independent studies (AFOSS and OPUS). Osteoporos Int 2010; 21: 457–66.
37. Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV, et al. Prediction of bone density from vitamin D receptor alleles. Nature 1994; 367: 284–7.
38. Choi HS. Vitamin D status in Korea. Endocrinol Metab (Seoul) 2013; 28: 12–6.
39. Kim KJ, Kim YJ, Kim SH, An JH, Yoo HJ, Kim HY, et al. Vitamin D status and associated metabolic risk factors among North Korean refugees in South Korea: a cross-sectional study. BMJ Open 2015; 5: e009140.